Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

NCT01206777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Indolent or Intermediate Grade B-cell Malignancy

Interventions

DRUG: Rituximab

Sponsor

Ohio State University Comprehensive Cancer Center